Clinical Trials Logo

Parathyroid Gland clinical trials

View clinical trials related to Parathyroid Gland.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05113628 Completed - Clinical trials for Recurrent Laryngeal Nerve Injuries

Methylene Blue Spray for Identification of Recurrent Laryngeal Nerve and Parathyroid Gland

Start date: January 15, 2020
Phase: N/A
Study type: Interventional

Thyroidectomy is the procedure by which surgeons treat various thyroid diseases and is considered the commonest endocrinal surgery. Yet, it carries a risk for intraoperative complications. The most distressing complications are recurrent laryngeal nerve and parathyroid injuries. Methylene blue spray is a technique than can be used for easy identification of both recurrent laryngeal nerve and parathyroid glands so we can avoid their injuries.

NCT ID: NCT04662437 Completed - COVID-19 Infection Clinical Trials

The Status of Parathyroid Hormone Secretion in Covid-19 Patients

Start date: September 10, 2020
Phase:
Study type: Observational

COVID-19 infection causes a hypersensitive immune reaction and widespread inflammation in various organs of the body, especially through cytokines in the lungs. This cytokine-mediated widespread inflammation can also affect the parathyroid glands, resulting in impaired parathyroid secretion. Researchers evaluated the levels of parathyroid hormone, calcium, phosphorus, and alkaline phosphatase in patients hospitalized for COVID-19 infection. Researchers excluded patients on intensive care therapy and patients with known parathyroid disease. The researchers examined the association of parathyroid hormone secretion with COVID-19 disease, white blood cells, neutrophil / lymphocyte ratio, C reactive protein, fibrinogen, procalcitonin, ferritin, and D-dimer in these patients. The researchers compared the parathyroid hormone level of healthy people without COVID-19 infection and known parathyroid disease with the parathyroid hormone level of Covid-19 patients.